Funders · Entity Annotation Prototype (beta)

1articles mentioning funders

1funder mentions

1distinct funders extracted

0%of mentions human-reviewed

Active filtersEntity: Moderna Inc. ×

Moderna Inc.

This funder is selected. Its supporting articles are shown below.

Moderna Inc.1

Articles mentioning Moderna Inc.

1 articles · page 1 of 1

590 A first-in-human, phase 1 trial of IMA203 PRAME-directed TCR T-cell therapy with PRAME-encoding mRNA-4203 in previously treated, unresectable or metastatic cutaneous melanoma or synovial sarcoma

jitc · abstract · 2025-11-04 · 1 matching annotations

75.6%

Immatics US, Inc.Moderna Inc.synovial sarcoma IMA203 cyclophosphamide mRNA-4203 PRAME SS fludarabine

…ients across 4 sites.Acknowledgements Study funding provided by Immatics US, Inc. and Moderna Inc.Trial Registration NCT06946225Reference Wermke …

Browse funders

Moderna Inc.

Articles mentioning Moderna Inc.

590 A first-in-human, phase 1 trial of IMA203 PRAME-directed TCR T-cell therapy with PRAME-encoding mRNA-4203 in previously treated, unresectable or metastatic cutaneous melanoma or synovial sarcoma